News

Filter

Current filters:

AmgenOncology

1 to 9 of 130 results

Amgen's Kyprolis doubles progression-free survival in head-to-head against Velcade

Amgen's Kyprolis doubles progression-free survival in head-to-head against Velcade

02-03-2015

USA-based biotech firm Amgen and its subsidiary Onyx Pharmaceuticals have announced the interim results…

AmgenBiotechnologyKyprolisOncologyResearchUSAVelcade

Three new drugs recommended for approval by EMA/CHMP

Three new drugs recommended for approval by EMA/CHMP

27-02-2015

Three new medicines have been recommended for approval at the February 2015 meeting of the European Medicines…

AmgenEuropeJinarcNephrology and HepatologyNovartisOncologyOtsuka PharmaceuticalPharmaceuticalRegulationRistempaVectibixZykadia

Amgen and Onyx’s MAA for Kyprolis is accepted by EMA

Amgen and Onyx’s MAA for Kyprolis is accepted by EMA

27-02-2015

The European Medicines Agency has accepted the Marketing Authorization Application for Kyprolis (carfilzomib)…

AmgenEuropeKyprolisOncologyOnyx PharmaceuticalsPharmaceuticalRegulation

Amgen and Onyx submit Kyprolis sNDA and marketing authorization application in USA and EU

Amgen and Onyx submit Kyprolis sNDA and marketing authorization application in USA and EU

28-01-2015

USA-based Amgen, the world’s leading independent biotech firm, and its subsidiary Onyx Pharmaceuticals…

AmgenKyprolisOncologyOnyx PharmaceuticalsPharmaceuticalRegulationUSA

Amgen trials show no differences in quality of life between the FOLFOX regimens with or without Vectibix

Amgen trials show no differences in quality of life between the FOLFOX regimens with or without Vectibix

16-01-2015

USA-based Amgen, the world’s leading independent biotech firm, says that Phase II and Phase III studies…

AmgenBiotechnologyOncologyResearchVectibix

Amgen to collaborate with University of Texas on BiTE technology

Amgen to collaborate with University of Texas on BiTE technology

13-01-2015

US biotech major Amgen is to collaborate with the MD Anderson Cancer Center at the University of Texas…

AmgenBiotechnologyOncologyResearchUSA

Sandoz’ Neupogen biosimilar backed by FDA advisory panel

Sandoz’ Neupogen biosimilar backed by FDA advisory panel

08-01-2015

The US Food and Drug Administration Oncologic Drugs Advisory Committee (ODAC), in a unanimous vote, recommended…

AmgenBiosimilarsBiotechnologyFilgrastimNeupogenNovartisOncologyRegulationSandozUSAZarxio

1 to 9 of 130 results

COMPANY SPOTLIGHT

Menarini

Back to top